Clinical Gastroenterology and Hepatology
Volume 7, Issue 11 , Pages 1151-1154, November 2009

Chronic Diarrhea Due to Excessive Bile Acid Synthesis and Not Defective Ileal Transport: A New Syndrome of Defective Fibroblast Growth Factor 19 Release

  • Alan F. Hofmann, MD

      Affiliations

    • Department of Medicine, University of California, San Diego, California
    • ,
  • David J. Mangelsdorf, PhD

      Affiliations

    • Department of Pharmacology, University of Texas, Southwestern Medical Center, Dallas, Texas
    • Howard Hughes Medical Institute, University of Texas, Southwestern Medical Center, Dallas, Texas
    • ,
  • Steven A. Kliewer, PhD

      Affiliations

    • Department of Pharmacology, University of Texas, Southwestern Medical Center, Dallas, Texas
    • Department of Molecular Biology, University of Texas, Southwestern Medical Center, Dallas, Texas

published online 10 August 2009.

Article Outline

 

Elsewhere in this issue Julian Walters and his colleagues report a major advance in our understanding of the pathogenesis of chronic diarrhea associated with idiopathic bile acid malabsorption.1 The story is a fascinating one and unites longstanding and very recent discoveries in physiology, biochemistry, and molecular biology.

Conjugated bile acids are absorbed from the terminal ileum by the combined action of an apical sodium-dependent transporter that takes bile acids into the cell and a basolateral transporter that takes bile acids out of the cell and into portal venous blood. The ileum was recognized as the preferential site of bile acid absorption by Tappeiner2 in 1878, and his observations were confirmed repeatedly. In 1960, Lack and Weiner3 used the everted gut sac technique to show that conjugated bile acids moved uphill, against a concentration gradient, in segments prepared from the distal ileum. Expression cloning was used by Paul Dawson and his colleagues to clone the apical sodium-dependent bile acid transporter in 1994.4 Seven years later, the heterodimeric basolateral transporter OSTα/OSTβ of the skate hepatocyte was cloned by Wang et al5 and Ballatori et al,6 and its essential role in the transport of bile acids across the basolateral membrane of the ileal enterocyte was established by Dawson et al.7

Bile acid biosynthesis from cholesterol is under negative feedback control. Interruption of the enterohepatic circulation by a biliary fistula8 or ileal dysfunction9, 10, 11, 12, 13 leads to a marked increase in bile acid biosynthesis. Pandak et al14 made the observation that such up-regulated bile acid synthesis could be down-regulated by bile acid infusion into the small intestine but not by intravenous infusion. This observation was confirmed and extended by a Japanese surgical group who showed that duodenal infusion down-regulated bile acid biosynthesis, whereas portal venous infusion did not.15 These experiments raised the intriguing possibility that an unknown intestinal factor was released by bile acids and was necessary for feedback inhibition of bile acid synthesis. Ten years later, this intestinal factor was discovered by Inagaki et al16 to be a protein, fibroblast growth factor (FGF) 19, an atypical FGF family member that functions as a hormone. FGF19 is synthesized in the ileal enterocytes in response to bile acids and released into the portal venous circulation. On reaching the liver, FGF19 signals through a cell surface receptor on hepatocytes to repress bile acid synthesis.

Increased bile acid biosynthesis in patients with bile acid malabsorption because of ileal dysfunction meant that more bile acids passed into the colon. A group of studies in animals and humans led by Sidney Phillips at the Mayo Clinic showed that colonic perfusion with dihydroxy bile salts induced colonic secretion,17, 18 and elevated concentrations of fecal bile acids were shown to be present in patients with ileal resection.9, 10, 11 The elevated concentrations were the result of greatly increased bile acid synthesis.9, 10, 11, 12, 13

It was quite straightforward to combine these findings and predict the sequence of events in patients undergoing ileal resection.19 Defective bile acid absorption led to increased hepatic synthesis. In this new steady state, increased bile acids passed into the colon and induced secretion, manifested clinically as diarrhea. If diarrhea were caused by bile acid–induced secretion in the colon, it should respond to a bile acid sequestrant. Indeed, cholestyramine was shown to be effective for the treatment of diarrhea in a small clinical study.20 Colesevelam, a more potent bile acid sequestrant, was developed a few years ago, and its off-label utility in diarrhea associated with bile acid malabsorption has been claimed in anecdotal reports.21 Colesevelam is available in tablet form and appears to be better tolerated than cholestyramine, which is marketed as a granular powder.

The diagnosis of bile acid malabsorption is not simple. One can measure fecal bile acids by gas chromatography22 or by an enzymatic method,23 but both methods are complex, and patients do not like to collect stool samples. Boyd, a Scottish biochemist, had the idea of synthesizing a taurocholate analogue tagged with a gamma emitting isotope. A 75selenium atom (a gamma particle emitter) was inserted into the side chain of the bile acid (between the 22nd and 23rd carbon atom), and this compound 75seleno-homocholyltaurine (SeHCAT) was shown to behave physiologically like taurocholate.24 In patients with bile acid malabsorption, the compound is lost from the body much more rapidly than in patients without bile acid malabsorption as quantified by whole body scanning with a gamma camera.25, 26, 27, 28 However, this valuable diagnostic radionuclide has never been available for clinical purposes in the United States.

A blood test for the detection of bile acid malabsorption would be more convenient. Gälman et al29 showed that an intermediate in bile acid synthesis named C4 (actually 7α-hydroxy-cholest-4-ene-3-one) spills over from the hepatocyte into plasma in direct proportion to the rate of bile acid synthesis. When bile acid synthesis was increased, plasma levels of C4 were markedly elevated.30, 31

In the meantime, the mechanistic details of the negative feedback regulation of bile acid biosynthesis in the hepatocyte were being clarified.32 An orphan member of the steroid hormone receptor family, named FXR, was discovered to be activated by bile acids and to play a central role in the regulation of bile acid homeostasis.33, 34, 35, 36 In the ileum, bile acid–mediated activation of FXR was shown to induce the synthesis and secretion of the protein hormone FGF19, which subsequently represses bile acid synthesis in hepatocytes by binding to a cell surface receptor composed of the FGF receptor 4, a tyrosine kinase, and β-klotho, a single pass transmembrane protein.37, 38, 39 Activation of the FGF receptor 4/β-klotho complex activates phosphorylation cascades that culminate in the transcriptional repression of the gene encoding cholesterol 7α-hydroxylase, the rate-limiting enzyme in bile acid synthesis.16, 40, 41 In mice, elimination of FXR, FGF15 (the mouse ortholog of FGF19), FGF receptor 4, or β-klotho increases cholesterol 7α-hydroxylase expression and bile acid synthesis,16, 42, 43, 44, 45 highlighting the importance of each of these proteins in the feedback regulatory pathway. This pathway of feedback inhibition of bile acid synthesis is illustrated in Figure 1.

  • View full-size image.
  • Figure 1. 

    Pathway by which the enterohepatic circulation of bile acids down-regulates bile acid biosynthesis. Bile acids traversing the ileal enterocyte activate FXR, the nuclear receptor for bile acids (shown as a heterodimer with RXR, the retinoid X receptor). FXR activation promotes the synthesis of FGF19, a protein that exits the ileal enterocyte by an unknown mechanism and travels to the liver in portal venous blood. FGF19 interacts with the dimeric receptor FGFR4/β-klotho present on the basolateral surface of the hepatocyte. The activated receptor initiates a phosphorylation cascade that culminates in the transcriptional repression of the gene encoding cholesterol 7α-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis.32 In patients with ileal dysfunction causing defective ileal transport of bile acids, the concentration of bile acids in the ileal enterocyte is low, and FGF19 formation and release are decreased, leading to increased hepatic bile acid biosynthesis that in turn causes diarrhea. In patients with idiopathic bile acid malabsorption, ileal bile acid transport is unimpaired. FGF19 release from the ileal enterocyte is impaired for unknown reasons, leading to increased hepatic bile acid biosynthesis that in turn causes diarrhea.

The late Hess Thaysen,46 working in Denmark, identified a group of patients who had bile acid malabsorption and diarrhea responsive to cholestyramine, yet they had no detectable ileal pathology. The defect has been termed primary bile acid malabsorption or idiopathic bile acid malabsorption. Merrick and colleagues showed that bile acid malabsorption was common in patients diagnosed as having irritable bowel syndrome, diarrhea predominant.47, 48 This observation was confirmed by Bardhan and his colleagues working in Rotherham, United Kingdom49 as well as in Italy50 and Sweden.51 It was logical to assume that such patients would have a defect in the gene encoding the ileal apical bile acid transporter. However, in a careful study by Montagnani et al,52 no defects in the gene encoding the apical sodium-dependent bile acid transporter (SLC10a2) were identified. Moreover, independent studies by van Tilburg et al53 and Bajor et al54 showed that conjugated bile acid transport by human ileal biopsy samples was not defective, but either normal or increased. Patients were also shown to have an enlarged bile acid pool55 and to be overweight.56

In this issue of Clinical Gastroenterology and Hepatology, Julian Walters and his colleagues1 present evidence for a new and fascinating explanation for the altered bile acid metabolism that is present in such patients. They describe a group of patients with chronic diarrhea responsive to cholestyramine who have bile acid malabsorption based on SeHCAT non-retention and increased plasma levels of C4. Their exciting discovery was that these patients had low plasma levels of FGF19. A low plasma level of FGF19 should in turn lead to defective negative feedback of bile acid biosynthesis and increased bile acid biosynthesis. In this new steady state, ileal transport should be saturated, and increased bile acids pass into the colon, inducing secretion that in turn is manifest clinically as diarrhea. This pathophysiologic defect can explain why van Tilburg et al53 and Bajor et al54 found unimpaired bile acid transport in their ileal biopsy samples and also explains why the bile acid pool is enlarged.55 It is not known why plasma levels of FGF19 are abnormally low, and this will surely be investigated. The pathophysiologic defect is also shown in Figure 1.

At last, we have a satisfying explanation for at least some cases of idiopathic bile acid malabsorption. Such patients should have increased bile acid biosynthesis and increased bile acid secretion. As noted above, the bile acid pool (measured by isotope dilution) is enlarged.55 Presumably, ileal transport is at its maximum, although some animal and human studies suggest that the ileal bile acid transport system should down-regulate when exposed to an increased flux of bile acids.57

The observation by the Walters group is the culmination of 50 years of research on the enterohepatic circulation of bile acids. For the physician, an explanation is now available for a subset of patients with chronic diarrhea. The diagnosis of bile acid malabsorption can be made by finding an increased plasma level of C4. However, a simple therapeutic trial of a bile acid sequestrant such as colesevelam or cholestyramine should generally be sufficient to establish the diagnosis and, if the patient responds, indicate successful therapy, providing symptomatic relief.

Back to Article Outline

References 

  1. Walters JRF, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009;7:1189–1194
  2. Tappeiner AJFH. Uber die Aufsaugung der Gallsäuren alkalien in Dünndarme. Wien Akad Sitzb. 1878;77:281–304
  3. Lack L, Weiner IM. Intestinal absorption of bile salts by small intestine of rats and guinea pigs. Am J Physiol. 1961;200:313–317
  4. Wong MH, Oelkers P, Craddock AL, et al. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J Biol Chem. 1994;269:1340–1347
  5. Wang W, Seward DJ, Li L, et al. Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate. Proc Natl Acad Sci U S A. 2001;98:9431–9436
  6. Ballatori N, Christian WV, Lee JY, et al. OSTalpha/OSTbeta: a major basolateral bile acid and steroid transporter in human, intestinal, renal, and biliary epithelia. Hepatology. 2005;42:1270–1279
  7. Dawson PA, Hubbert M, Haywood J, et al. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem. 2006;280:6960–6968
  8. Shefer S, Hauser S, Bekersky I, et al. Feedback regulation of bile acid biosynthesis in the rat. J Lipid Res. 1969;10:646–655
  9. Hofmann AF, Poley JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection (I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride). Gastroenterology. 1972;62:918–934
  10. Aldini R, Roda A, Festi D, et al. Bile acid malabsorption and bile acid diarrhea in intestinal resection. Dig Dis Sci. 1982;27:495–502
  11. McJunkin B, Fromm H, Sarva RP, et al. Factors in the mechanism of diarrhea in bile acid malabsorption: fecal pH—a key determinant. Gastroenterology. 1981;80:1454–1464
  12. Grundy SM, Ahrens EH, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 1971;78:94–121
  13. Miettinen TA. Relationship between faecal bile acids, absorption of fat and vitamin B 12 and serum lipids in patients with ileal resections. Eur J Clin Invest. 1971;1:452–460
  14. Pandak WM, Heuman DM, Hylemon PB, et al. Failure of intravenous infusion of taurocholate to down-regulate cholesterol 7 alpha-hydroxylase in rats with biliary fistulas. Gastroenterology. 1995;108:533–544
  15. Nagano M, Kuroki S, Mizuta A, et al. Regulation of bile acid synthesis under reconstructed enterohepatic circulation in rats. Steroids. 2004;69:701–709
  16. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–225
  17. Mekhjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest. 1971;50:1569–1577
  18. Chadwick VS, Gaginella TS, Carlson GL, et al. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability and morphology in the perfused rabbit colon. J Lab Clin Med. 1979;94:661–674
  19. Hofmann AF. The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. Gastroenterology. 1967;52:752–757
  20. Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med. 1969;281:397–402
  21. Puleston J, Morgan H, Andreyev J. New treatment for bile salt malabsorption. Gut. 2005;54:441–442
  22. Grundy SM, Ahrens EH, Miettinen TA. Quantitative isolation and gas-liquid chromatographic analysis of total fecal bile acids. J Lipid Res. 1965;6:397–410
  23. Porter JL, Fordtran JS, Santa Ana CA, et al. A simple and accurate enzymatic method for measurement of total fecal bile acids in patients with severe fat malabsorption. J Lab Clin Med. 2003;141:411–418
  24. Hofmann AF, Bolder U. Detection of bile acid malabsorption by the SeHCAT test: principles, problems and clinical utility. Gastroenterol Clin Biol. 1994;18:847–851
  25. Thaysen EH, Orholm NM, Arnefred T, et al. Assessment of ileal function by abdominal counting of the retention of a gamma emitting bile acid analogue. Gut. 1982;23:862–865
  26. Brydon WG, Nyhlin H, Eastwood MA, et al. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol. 1996;8:117–123
  27. Sciarretta G, Fagioli G, Furno A, et al. 75SeHCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut. 1987;28:970–975
  28. Fellous K, Jian R, Haniche M, et al. Mesure de l'absorption ileale des sels biliaires par le test a l'homotaurocholate marquee au selenium 75: validation et signification clinique. Gastroenterol Clin Biol. 1994;18:865–872
  29. Gälman C, Arvidsson T, Angelin B, et al. Monitoring hepatic cholesterol 7 alpha-hydroxylase activity by assay of the stable bile acid intermediate 7 alpha-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res. 2003;44:859–866
  30. Eusufzai S, Axelson M, Angelin B, et al. Serum 7alpha-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test. Gut. 1993;34:698–701
  31. Sauter GH, Munzing W, von Ritter C, et al. Bile acid malabsorption a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholest-3-one in serum. Dig Dis Sci. 1999;44:14–19
  32. Chiang JYL. Bile acids: regulation of synthesis. J Lipid Res. 2009;Apr 3 [Epub ahead of print]
  33. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365–1368
  34. Makashima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365
  35. Wang H, Chen J, Holister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3:543–553
  36. Lu TT, Makashima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6:507–515
  37. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007;27:3417–3428
  38. Lin BC, Wang M, Blackmore C, et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem. 2007;282:27277–27284
  39. Wu X, Ge H, Gupte J, et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem. 2007;282:29069–29072
  40. Holt JA, Luo G, Billin AN, et al. Description of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581–1591
  41. Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 2009;49:297–305
  42. Kok T, Hulzebos CV, Wolters H, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem. 2003;278:41930–41937
  43. Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744
  44. Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem. 2000;275:15482–15489
  45. Ito S, Fujimori T, Furuya A, et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest. 2005;115:2202–2208
  46. Thaysen EH. Idiopathic bile acid diarrhoea reconsidered. Scand J Gastroenterol. 1985;20:452–456
  47. Merrick MV, Eastwood MA, Ford MJ. Is bile acid malabsorption underdiagnosed? (An evaluation of diagnosis by measurement of SeHCAT retention). Br Med J (Clin Res Ed). 1985;290:665–668
  48. Williams AJ, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption: a review of clinical presentation, diagnosis, and response to treatment. Gut. 1991;32:1004–1006
  49. Smith MJ, Cherian P, Raju GS, et al. Bile salt malabsorption in persistent diarrhoea. J R Coll Physicians Lond. 2000;34:448–451
  50. Galatola G. The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: an uncontrolled open multicentre study. Eur J Gastroenterol Hepatol. 1992;4:533–537
  51. Wildt S, Norby Rasmussen S, Lysgard Madsen J, et al. Bile acid malabsorption in patients with chronic diarrhoea: clinical value of SeHCAT test. Scand J Gastroenterol. 2003;38:826–830
  52. Montagnani M, Love MW, Rossel P, et al. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand J Gastroenterol. 2001;36:1077–1080
  53. vanTilburg AJ, de Rooij FW, van den Berg JW, et al. Primary bile acid diarrhoea without an ileal carrier defect: quantification of active bile acid transport across the ileal brush border membrane. Gut. 1991;32:500–503
  54. Bajor A, Kilander A, Fae A, et al. Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption. Eur J Gastroenterol Hepatol. 2006;18:397–403
  55. van Tilburg AJ, de Rooij FW, van den Bergh , et al. Primary bile acid malabsorption: a pathophysiologic and clinical entity?. Scand J Gastroenterol Suppl. 1992;194:66–70
  56. Sadik R, Abrahamsson H, Ung K-A, et al. Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol. 2004;49:711–718
  57. Lillienau J, Munoz J, Longmire-Cook SJ, et al. Negative feedback regulation of the ileal bile acid transport system in rodents. Gastroenterology. 1993;104:38–46

 Conflicts of interest The authors disclose the following: All of the authors have served as ad hoc consultants to Daiichi Sankyo Inc, who market colesevelam for the treatment of type 2 diabetes in the United States.

 Funding This work was supported by National Institutes of Health grant DK067158 and the Welch Foundation (D.J.M. and S.A.K.) and the Howard Hughes Medical Institute (D.J.M.).

PII: S1542-3565(09)00745-9

doi:10.1016/j.cgh.2009.07.026

Clinical Gastroenterology and Hepatology
Volume 7, Issue 11 , Pages 1151-1154, November 2009